Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...

Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...